HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gabriel N Hortobagyi Selected Research

Messenger RNA (mRNA)

9/2017Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.
7/2017Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.
11/2013Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.
3/2012Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1.
3/2012Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.
2/2012Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
5/2009Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
4/2009The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
4/2007Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
3/2007Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gabriel N Hortobagyi Research Topics

Disease

419Breast Neoplasms (Breast Cancer)
10/2022 - 01/2002
268Neoplasms (Cancer)
01/2022 - 01/2002
64Neoplasm Metastasis (Metastasis)
05/2021 - 06/2002
43Pathologic Complete Response
01/2022 - 06/2005
27Triple Negative Breast Neoplasms
01/2022 - 03/2008
22Disease Progression
12/2021 - 04/2002
16Inflammatory Breast Neoplasms
10/2021 - 01/2003
12Residual Neoplasm
01/2018 - 04/2004
11Circulating Neoplastic Cells
01/2022 - 03/2005
9Cardiotoxicity
10/2021 - 11/2002
7Neutropenia
01/2019 - 07/2003
6Ovarian Neoplasms (Ovarian Cancer)
01/2019 - 11/2002
6Carcinogenesis
07/2014 - 03/2004
5Obesity
10/2021 - 09/2008
5Infections
05/2021 - 10/2002
5Peripheral Nervous System Diseases (PNS Diseases)
11/2018 - 11/2012
5Noninfiltrating Intraductal Carcinoma (DCIS)
10/2014 - 06/2002
5Heart Failure
11/2013 - 11/2002
4Fatigue
01/2019 - 02/2004
4Febrile Neutropenia
01/2019 - 01/2003
4Pain (Aches)
01/2016 - 06/2002

Drug/Important Bio-Agent (IBA)

78Hormones (Hormone)IBA
10/2022 - 10/2002
69Estrogen ReceptorsIBA
11/2021 - 01/2002
48Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 01/2002
46AnthracyclinesIBA
10/2021 - 02/2002
45Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2022 - 01/2002
42Trastuzumab (Herceptin)FDA Link
12/2019 - 04/2002
38Paclitaxel (Taxol)FDA LinkGeneric
10/2020 - 05/2002
34Biomarkers (Surrogate Marker)IBA
12/2019 - 06/2002
34Fluorouracil (Carac)FDA LinkGeneric
01/2019 - 01/2002
33human ERBB2 proteinIBA
10/2022 - 01/2004
32taxaneIBA
11/2018 - 02/2002
31Proteins (Proteins, Gene)FDA Link
09/2017 - 09/2003
30Progesterone Receptors (Progesterone Receptor)IBA
10/2020 - 10/2002
25ErbB Receptors (EGF Receptor)IBA
12/2021 - 10/2002
19Pharmaceutical PreparationsIBA
01/2021 - 06/2002
19TamoxifenFDA LinkGeneric
01/2020 - 01/2002
19Docetaxel (Taxotere)FDA Link
04/2014 - 01/2002
18EverolimusFDA Link
01/2022 - 10/2007
17DNA (Deoxyribonucleic Acid)IBA
01/2019 - 03/2004
17Biological ProductsIBA
01/2017 - 10/2002
16Aromatase InhibitorsIBA
01/2019 - 03/2004
16Taxoids (Taxanes)IBA
10/2015 - 05/2002
15Estrogens (Estrogen)FDA Link
01/2020 - 07/2003
15exemestane (Aromasin)FDA Link
01/2019 - 03/2004
12Diphosphonates (Bisphosphonates)IBA
05/2021 - 10/2003
12Epidermal Growth Factor (EGF)IBA
10/2020 - 10/2007
12Messenger RNA (mRNA)IBA
09/2017 - 06/2005
11Phosphotransferases (Kinase)IBA
01/2019 - 05/2003
9Zoledronic Acid (Zometa)FDA Link
05/2021 - 01/2005
9Capecitabine (Xeloda)FDA Link
03/2012 - 09/2003
8Anastrozole (Arimidex)FDA LinkGeneric
01/2022 - 06/2002
8Bevacizumab (Avastin)FDA Link
01/2018 - 10/2004
8Lapatinib (GW572016)FDA Link
07/2014 - 07/2008
7Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2022 - 04/2004
7Monoclonal AntibodiesIBA
01/2022 - 06/2002
7RNA (Ribonucleic Acid)IBA
10/2021 - 06/2003
7Immune Checkpoint InhibitorsIBA
01/2021 - 07/2017
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2019 - 08/2007
7Indicators and Reagents (Reagents)IBA
01/2019 - 11/2002
7Epirubicin (Ellence)FDA LinkGeneric
11/2015 - 06/2005
7Tyrosine Kinase InhibitorsIBA
07/2014 - 06/2003
6Letrozole (Femara)FDA LinkGeneric
10/2022 - 11/2016
6ribociclibIBA
10/2022 - 11/2016
6LigandsIBA
01/2021 - 12/2009
6Biological FactorsIBA
10/2020 - 07/2016
6Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2020 - 07/2015
6ParaffinIBA
12/2019 - 04/2004
6Cyclin-Dependent Kinases (cdk Proteins)IBA
01/2019 - 10/2006
6Tumor Biomarkers (Tumor Markers)IBA
10/2014 - 10/2002
6Transcription Factors (Transcription Factor)IBA
02/2012 - 09/2003
5Phenobarbital (Luminal)FDA Link
11/2019 - 08/2005
5Antineoplastic Agents (Antineoplastics)IBA
01/2019 - 01/2007
5Metformin (Glucophage)FDA LinkGeneric
01/2019 - 07/2009
5ixabepilone (BMS 247550)FDA Link
10/2015 - 08/2007
5Granulocyte Colony-Stimulating Factor (G-CSF)IBA
03/2011 - 01/2002
5Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2011 - 06/2007
4Fulvestrant (Faslodex)FDA Link
01/2022 - 08/2012
4CytokinesIBA
01/2021 - 02/2004
4Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
01/2020 - 01/2013
4Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
01/2019 - 01/2008
4Methotrexate (Mexate)FDA LinkGeneric
01/2019 - 11/2003
4TOR Serine-Threonine KinasesIBA
01/2019 - 02/2012
4Tyrosine (L-Tyrosine)FDA Link
01/2019 - 08/2007
4GemcitabineFDA Link
01/2018 - 05/2002
4Cyclin EIBA
06/2017 - 11/2002
4Dasatinib (BMS 354825)FDA Link
12/2016 - 05/2010
4Selective Estrogen Receptor Modulators (SERM)IBA
01/2016 - 03/2004
4RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
12/2015 - 05/2005
4Vinorelbine (Navelbine)FDA LinkGeneric
01/2014 - 01/2002

Therapy/Procedure

186Therapeutics
10/2022 - 01/2002
154Drug Therapy (Chemotherapy)
12/2021 - 01/2002
78Neoadjuvant Therapy
01/2022 - 01/2002
32Radiotherapy
10/2021 - 06/2002
31Adjuvant Chemotherapy
12/2019 - 01/2002
15Mastectomy (Mammectomy)
06/2014 - 01/2002
11Segmental Mastectomy (Lumpectomy)
10/2021 - 07/2002
8Aftercare (After-Treatment)
01/2021 - 07/2002
4Precision Medicine
01/2021 - 11/2006
4Prophylactic Mastectomy
10/2014 - 12/2007